相关实验视频

Updated: Jun 29, 2025

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

miR-1246通过依赖Argonaute 2的NamiRNA增强器网络促进骨髓瘤细胞迁移

Shuai Yang¹, Qingping Zou¹, Ying Liang¹

¹Shanghai Public Health Clinical Centre and Department of General Surgery Huashan Hospital Cancer Metastasis Institute and Laboratory of RNA Epigenetics Institutes of Biomedical Sciences Shanghai Medical College Fudan University Shanghai China.

|April 8, 2024

概括

核miR-1246激活基因表达,增强骨髓瘤细胞迁移. 核AGO2保护了这一过程,为转移提供了治疗点.

科学领域:

分子生物学分子生物学
癌症研究癌症研究
表观遗传学在表观遗传学中,表观遗传学是指表观遗传学.

背景情况:

骨髓瘤转移是治疗失败的主要原因.
核激活型微RNAs (NamiRNAs) 可以通过向增强剂来促进瘤转移.
纳米RNAs在骨髓瘤转移中的特定作用及其机制仍然不清楚.

研究的目的:

研究NamiRNAs在骨髓瘤转移中的作用.
阐明纳米RNAs调节骨髓瘤中基因表达和细胞迁移的机制.
为了确定骨髓瘤转移的潜在治疗点.

主要方法:

来自恶性骨髓瘤细胞 (143B) 的细胞外囊被用于治疗良性骨髓瘤细胞 (MNNG).
评估了miR-1246的水平及其核定位.
测量了增强剂活性,H3K27ac丰富度和MMP1表达.
为了研究AGO2的作用,Argonaute 2 (AGO2) 敲击和体外试验进行了测试.

主要成果:

来自143B细胞的细胞外囊泡显著增加了MNNG细胞迁移,这归因于升高的miR-1246.
核miR-1246通过增加增强剂活性和H3K27ac丰富来激活迁移基因表达 (例如,MMP1).
通过AGO2敲击抑制了MMP1的表达.
AGO2保护miR-1246 /增强剂DNA杂交物免受降解,促进基因激活.

结论:

miR-1246通过通过增强剂相互作用激活基因表达来促进骨髓瘤转移,这取决于核AGO2.2.
核AGO2作为NamiRNA介导基因激活的保护因子.
miR-1246和核AGO2代表了骨髓瘤转移的潜在治疗点.

关键词:

阿尔戈诺特人 2 2 增强剂是一种增强剂.转移转移转移转移在 miR-124646 的情况下,核激活miRNAs的核激活骨质肉瘤是骨质肉瘤的一种疾病.

更多相关视频

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

相关概念视频

MicroRNAs

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Experimental RNAi

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...

Cancer Cell Migration through Invadopodia

Cancer Cell Migration through Invadopodia

Invadosome is a broad category of cell surface structures with proteolytic activity that degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...